Clearfield (CLFD) closed the last trading session at $36.36, gaining 37.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $46 indicates a 26.5% upside potential.The average comprises four short-term price targets ranging from a low of $44 to a high of $50, with a standard deviation of $2.71. While the lowest estimate indicates an increase of 21% from the current price level, the m ...

Shares of ClearPoint Neuro, Inc. (CLPT) have gained 18.2% over the past four weeks to close the last trading session at $13.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.67 indicates a potential upside of 102.9%.The average comprises three short-term price targets ranging from a low of $25 to a high of $30, with a standard deviation of $2.52. While the lowest estimate ...

Core Viewpoint - Cogent Biosciences, Inc. (COGT) shows significant upside potential with a mean price target of $16.64, indicating a 224.4% increase from the current price of $5.13 [1] Price Targets and Analyst Consensus - The average of 11 short-term price targets ranges from a low of $7 to a high of $24, with a standard deviation of $5.28, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 36.5% increase, while the most optimistic estimate points to a 367.8% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about COGT's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 3% over the past month, with one estimate going higher and no negative revisions [12] - COGT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Easterly Government Properties (DEA) has shown a slight increase of 0.1% in share price over the past four weeks, closing at $20.92, with a potential upside of 35% based on Wall Street analysts' mean price target of $28.25 [1][11]. Price Targets and Analyst Estimates - The mean estimate for DEA comprises five short-term price targets with a standard deviation of $3.26, indicating variability among analysts. The lowest estimate suggests a 13.5% increase to $23.75, while the highest target predicts a 55.4% surge to $32.50 [2][9]. - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about DEA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11][12]. - The Zacks Consensus Estimate for DEA has increased by 0.8% over the past month, reflecting a positive revision trend with no negative adjustments [12]. Zacks Rank and Investment Potential - DEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [13].

Shares of Intapp (INTA) have gained 7.3% over the past four weeks to close the last trading session at $56.31, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $71 indicates a potential upside of 26.1%.The mean estimate comprises eight short-term price targets with a standard deviation of $7.95. While the lowest estimate of $60 indicates a 6.6% increase from the current price lev ...

Core Viewpoint - Honest (HNST) shares have increased by 14.5% in the past four weeks, closing at $5.07, with a potential upside indicated by Wall Street analysts' mean price target of $7.14, suggesting a 40.8% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $0.85, where the lowest estimate is $5.50 (8.5% increase) and the highest is $8 (57.8% increase) [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about HNST's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 47.6% over the past month, with two estimates increasing and no negative revisions [12] - HNST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Shares of Kemper (KMPR) have gained 12.8% over the past four weeks to close the last trading session at $65.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $82.20 indicates a potential upside of 25.5%.The mean estimate comprises five short-term price targets with a standard deviation of $5.72. While the lowest estimate of $75 indicates a 14.5% increase from the current price ...

Core Viewpoint - Centrus Energy Corp. (LEU) has shown a significant price increase of 46% over the past four weeks, with a mean price target of $148.33 indicating a potential upside of 56.6% from the current price of $94.71 [1] Price Targets and Analyst Consensus - The average price target for LEU includes six short-term estimates, ranging from a low of $69 to a high of $300, with a standard deviation of $79.84, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 27.2%, while the highest points to a potential upside of 216.8% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about LEU's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 9.9% increase in the Zacks Consensus Estimate over the past month [11][12] - The company currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - 10x Genomics (TXG) shares have increased by 14.7% recently, with a mean price target of $14.79 suggesting a potential upside of 55.9% from the current price of $9.49 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $3.79, indicating variability among analysts [2] - The lowest estimate of $11 indicates a 15.9% increase, while the highest estimate suggests a 174% surge to $26 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TXG's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 14.6%, with five estimates moving higher and no negative revisions [12] - TXG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of Spyre Therapeutics (SYRE) have gained 14.7% over the past four weeks to close the last trading session at $14.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $53.50 indicates a potential upside of 258.3%.The mean estimate comprises 10 short-term price targets with a standard deviation of $16.36. While the lowest estimate of $21 indicates a 40.7% increase from the c ...